<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Formation of fibrin is critical for limiting blood loss at a site of blood vessel injury (hemostasis), but may also contribute to vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Hereditary deficiency of factor XII (FXII), the protease that triggers the intrinsic pathway of coagulation in vitro, is not associated with spontaneous or excessive injury-related <z:mp ids='MP_0001914'>bleeding</z:mp>, indicating FXII is not required for hemostasis </plain></SENT>
<SENT sid="2" pm="."><plain>We demonstrate that deficiency or inhibition of FXII protects mice from ischemic brain injury </plain></SENT>
<SENT sid="3" pm="."><plain>After transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, the volume of infarcted brain in FXII-deficient and FXII inhibitor-treated mice was substantially less than in <z:mp ids='MP_0002169'>wild-type</z:mp> controls, without an increase in <z:mpath ids='MPATH_124'>infarct</z:mpath>-associated <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Targeting FXII reduced fibrin formation in ischemic vessels, and reconstitution of FXII-deficient mice with human FXII restored <z:mpath ids='MPATH_179'>fibrin deposition</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Mice deficient in the FXII substrate factor XI were similarly protected from vessel-occluding fibrin formation, suggesting that FXII contributes to pathologic clotting through the intrinsic pathway </plain></SENT>
<SENT sid="6" pm="."><plain>These data demonstrate that some processes involved in pathologic <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation are distinct from those required for <z:mpath ids='MPATH_458'>normal</z:mpath> hemostasis </plain></SENT>
<SENT sid="7" pm="."><plain>As FXII appears to be instrumental in pathologic fibrin formation but dispensable for hemostasis, FXII inhibition may offer a selective and safe strategy for preventing <z:hpo ids='HP_0001297'>stroke</z:hpo> and other <z:hpo ids='HP_0001907'>thromboembolic diseases</z:hpo> </plain></SENT>
</text></document>